|
GB532822A
(en)
|
1939-08-11 |
1941-01-31 |
John David Kendall |
Improvements in and relating to the production of ª‡-coumarilyl and ª‡-thionaphthenoyl-acetic acid esters
|
|
US4299769A
(en)
|
1980-04-28 |
1981-11-10 |
American Cyanamid Company |
ω-Heteroaroyl(propionyl or butyryl)-L-prolines
|
|
US4342691A
(en)
|
1980-04-28 |
1982-08-03 |
American Cyanamid Company |
ω-Heteroaroyl(propionyl or butyryl)-L-prolines
|
|
US4342690A
(en)
|
1980-04-28 |
1982-08-03 |
American Cyanamid Company |
ω-Heteroaroyl(propionyl or butyryl)-L-prolines
|
|
US4342689A
(en)
|
1980-04-28 |
1982-08-03 |
American Cyanamid Company |
ω-Heteroaroyl(propionyl or butyryl)-L-prolines
|
|
EP0146243A1
(en)
|
1983-10-31 |
1985-06-26 |
Merck Frosst Canada Inc. |
Lipoxygenase inhibitors
|
|
DE68924308T2
(de)
|
1988-07-11 |
1996-04-04 |
Akzo Nobel Nv |
Pyridazinon-Derivate.
|
|
AU675680B2
(en)
|
1992-10-14 |
1997-02-13 |
Merck & Co., Inc. |
Fibrinogen receptor antagonists
|
|
US5569655A
(en)
|
1993-09-14 |
1996-10-29 |
Sterling Winthrop Inc. |
Substituted heterocyclylisoquinolinium salts and compositions and method of use thereof
|
|
AU757409B2
(en)
|
1998-06-03 |
2003-02-20 |
Merck & Co., Inc. |
Hiv integrase inhibitors
|
|
US6262055B1
(en)
|
1998-06-03 |
2001-07-17 |
Merck & Co., Inc. |
HIV integrase inhibitors
|
|
PE20010306A1
(es)
|
1999-07-02 |
2001-03-29 |
Agouron Pharma |
Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
|
|
GB0018891D0
(en)
|
2000-08-01 |
2000-09-20 |
Novartis Ag |
Organic compounds
|
|
JP2003528074A
(ja)
|
2000-03-24 |
2003-09-24 |
メチルジーン インコーポレイテッド |
ヒストン脱アセチル化酵素の阻害剤
|
|
US6448288B1
(en)
|
2000-05-17 |
2002-09-10 |
University Of Massachusetts |
Cannabinoid drugs
|
|
AU2002234755A1
(en)
|
2001-02-26 |
2002-09-12 |
Pharma Pacific Pty Ltd |
Interferon-alpha induced gene
|
|
DE60334303D1
(de)
|
2002-07-03 |
2010-11-04 |
Tasuku Honjo |
Immunpotenzierende zusammensetzungen
|
|
ES2367430T3
(es)
|
2002-12-23 |
2011-11-03 |
Wyeth Llc |
Anticuerpos contra pd-1 y sus usos.
|
|
US7563869B2
(en)
|
2003-01-23 |
2009-07-21 |
Ono Pharmaceutical Co., Ltd. |
Substance specific to human PD-1
|
|
AU2004268012B2
(en)
|
2003-09-02 |
2008-11-20 |
Merck & Co., Inc. |
Ophthalmic compositions for treating ocular hypertension
|
|
WO2005089777A1
(en)
|
2004-03-15 |
2005-09-29 |
Karaolis David K R |
A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
|
|
EP3530736A3
(en)
|
2005-05-09 |
2019-11-06 |
ONO Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
|
KR101704734B1
(ko)
|
2005-07-01 |
2017-02-09 |
이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
|
|
AU2006304897B2
(en)
|
2005-10-18 |
2012-07-12 |
Janssen Pharmaceutica N.V. |
Method of inhibiting FLT3 kinase
|
|
EP1782826A1
(en)
|
2005-11-08 |
2007-05-09 |
GBF Gesellschaft für Biotechnologische Forschung mbH |
PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
|
|
CA2673870A1
(en)
|
2006-12-27 |
2008-07-10 |
Emory University |
Compositions and methods for the treatment of infections and tumors
|
|
PT2170959E
(pt)
|
2007-06-18 |
2014-01-07 |
Merck Sharp & Dohme |
Anticorpos para o receptor humano de morte programada pd-1
|
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
|
WO2010098788A2
(en)
|
2008-08-25 |
2010-09-02 |
Amplimmune, Inc. |
Pd-i antagonists and methods for treating infectious disease
|
|
WO2010036959A2
(en)
|
2008-09-26 |
2010-04-01 |
Dana-Farber Cancer Institute |
Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
|
|
US8664255B2
(en)
|
2008-10-20 |
2014-03-04 |
The Texas A&M University System |
Inhibitors of mycobacterium tuberculosis malate synthase, methods of making and uses thereof
|
|
MX356367B
(es)
|
2008-12-09 |
2018-05-25 |
Genentech Inc |
Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
|
|
EP2504028A4
(en)
|
2009-11-24 |
2014-04-09 |
Amplimmune Inc |
SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
|
|
WO2012068702A1
(zh)
|
2010-11-23 |
2012-05-31 |
中国医学科学院医药生物技术研究所 |
苯并五元不饱和杂环类化合物及其制备方法
|
|
JP5887947B2
(ja)
|
2011-03-28 |
2016-03-16 |
ソニー株式会社 |
透明導電膜、ヒータ、タッチパネル、太陽電池、有機el装置、液晶装置および電子ペーパ
|
|
EP2697242B1
(en)
|
2011-04-13 |
2018-10-03 |
Merck Sharp & Dohme Corp. |
2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
|
BR112014002353B1
(pt)
|
2011-08-01 |
2022-09-27 |
Genentech, Inc |
Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit
|
|
EP2858722B8
(en)
|
2012-06-08 |
2018-02-21 |
Aduro BioTech, Inc. |
Compostions and methods for cancer immunotherapy
|
|
SG11201502796RA
(en)
|
2012-12-13 |
2015-05-28 |
Aduro Biotech Inc |
Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
|
|
JP2016506408A
(ja)
|
2012-12-19 |
2016-03-03 |
ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム |
哺乳動物の環状ジヌクレオチドシグナル伝達経路の薬学的標的化
|
|
US9211300B2
(en)
|
2012-12-19 |
2015-12-15 |
Idenix Pharmaceuticals Llc |
4′-fluoro nucleosides for the treatment of HCV
|
|
WO2014139388A1
(en)
|
2013-03-14 |
2014-09-18 |
Merck Sharp & Dohme Corp. |
Novel indole derivatives useful as anti-diabetic agents
|
|
JP2016524593A
(ja)
|
2013-04-29 |
2016-08-18 |
メモリアル スローン−ケタリング キャンサー センター |
セカンドメッセンジャーのシグナル伝達を変えるための組成物及び方法
|
|
CN105377867B
(zh)
|
2013-05-03 |
2019-11-12 |
加利福尼亚大学董事会 |
I型干扰素的环状二核苷酸诱导
|
|
CU24377B1
(es)
|
2013-05-18 |
2018-12-05 |
Aduro Biotech Inc |
Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting
|
|
EP2996472B1
(en)
|
2013-05-18 |
2019-03-27 |
Aduro Biotech, Inc. |
Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling
|
|
US10176292B2
(en)
|
2013-07-31 |
2019-01-08 |
Memorial Sloan-Kettering Cancer Center |
STING crystals and modulators
|
|
JP2016538344A
(ja)
|
2013-11-19 |
2016-12-08 |
ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago |
癌処置としてのstingアゴニストの使用
|
|
EP3071229A4
(en)
|
2013-11-22 |
2017-05-10 |
Brock University |
Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
|
|
US9315523B2
(en)
|
2013-12-06 |
2016-04-19 |
Rutgers, The State University Of New Jersey |
Cyclic dinucleosides
|
|
WO2015143712A1
(en)
|
2014-03-28 |
2015-10-01 |
Merck Sharp & Dohme Corp. |
4'-substituted nucleoside reverse transcriptase inhibitors
|
|
EP3131914B1
(en)
|
2014-04-16 |
2023-05-10 |
Idenix Pharmaceuticals LLC |
3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
|
|
CN103908468B
(zh)
|
2014-04-21 |
2017-02-08 |
上海捌加壹医药科技有限公司 |
环二核苷酸cGAMP在制备抗肿瘤药物中的应用
|
|
EP3152217B1
(en)
|
2014-06-04 |
2018-08-01 |
GlaxoSmithKline Intellectual Property Development Limited |
Cyclic di-nucleotides as modulators of sting
|
|
WO2015189117A1
(de)
|
2014-06-12 |
2015-12-17 |
Bayer Pharma Aktiengesellschaft |
Heterobicyclisch substituierte 4-oxobutansäure-derivate und ihre verwendung
|
|
US10695426B2
(en)
|
2014-08-25 |
2020-06-30 |
Pfizer Inc. |
Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
|
|
EP3233191A1
(en)
|
2014-12-16 |
2017-10-25 |
Invivogen |
Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment
|
|
DK3233882T3
(da)
|
2014-12-16 |
2020-01-27 |
Kayla Therapeutics |
Fluorinerede cykliske dinukleotider til cytokininduktion
|
|
EP3233089A4
(en)
|
2014-12-17 |
2018-11-14 |
Lipogen LLC |
Method of treating cancer with cgamp or cgasmp
|
|
GB201501462D0
(en)
|
2015-01-29 |
2015-03-18 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
TWI706958B
(zh)
|
2015-03-10 |
2020-10-11 |
美商艾杜諾生物科技公司 |
活化「干擾素基因刺激因子」依賴性訊息傳導之組合物及方法
|
|
TW201717968A
(zh)
|
2015-07-14 |
2017-06-01 |
春季銀行製藥公司 |
誘導rig-i和其他模式辨識受體之化合物及組成物
|
|
WO2017011920A1
(en)
|
2015-07-22 |
2017-01-26 |
The Royal Institution For The Advancement Of Learning/Mcgill University |
Compounds and uses thereof in the treatment of cancers and other medical conditions
|
|
EP3328418A1
(en)
|
2015-07-29 |
2018-06-06 |
Novartis AG |
Combination therapies comprising antibody molecules to pd-1
|
|
CN108137641B
(zh)
|
2015-08-13 |
2022-04-01 |
默沙东公司 |
作为sting激动剂的环状双核苷酸化合物
|
|
US9809597B2
(en)
|
2015-08-20 |
2017-11-07 |
The Board Of Trustees Of The Leland Stanford Junior University |
Ganciclovir derivatives for modulating innate and adaptive immunity and for use in immunotherapy
|
|
KR20180066241A
(ko)
|
2015-10-28 |
2018-06-18 |
아두로 바이오테크, 인코포레이티드 |
“인터페론 유전자의 자극제”-의존성 신호전달을 활성화시키기 위한 조성물 및 방법
|
|
US20170146519A1
(en)
|
2015-11-20 |
2017-05-25 |
Oregon Health & Science University |
Sting agonists and methods of selecting sting agonists
|
|
JP6411676B2
(ja)
*
|
2015-12-03 |
2018-10-24 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
Stingの調節因子としての環状プリンジヌクレオチド
|
|
DE212016000029U1
(de)
|
2015-12-07 |
2017-07-30 |
Opi Vi - Ip Holdco Llc |
Zusammensetzungen von Antikörperkonstrukt-Agonist-Konjugaten
|
|
CN108495651A
(zh)
|
2015-12-17 |
2018-09-04 |
诺华股份有限公司 |
抗pd-1的抗体分子及其用途
|
|
SMT202500412T1
(it)
|
2016-01-11 |
2025-11-10 |
Innate Tumor Immunity Inc |
Dinucleotidi ciclici per il trattamento di condizioni associate all’attività di sting quali il cancro
|
|
WO2017123657A1
(en)
|
2016-01-11 |
2017-07-20 |
Gary Glick |
Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
|
|
IL280430B2
(en)
|
2016-03-18 |
2023-11-01 |
Univ Texas |
Cyclic dinucleotide compounds and methods of use
|
|
SG10201900628RA
(en)
|
2016-04-07 |
2019-02-27 |
Glaxosmithkline Ip Dev Ltd |
Heterocyclic amides useful as protein modulators
|
|
WO2017175156A1
(en)
|
2016-04-07 |
2017-10-12 |
Glaxosmithkline Intellectual Property Development Limited |
Heterocyclic amides useful as protein modulators
|
|
SG11201809559UA
(en)
|
2016-06-13 |
2018-12-28 |
Glaxosmithkline Ip Dev Ltd |
Substituted pyridines as inhibitors of dnmt1
|
|
EP3507367A4
(en)
|
2016-07-05 |
2020-03-25 |
Aduro BioTech, Inc. |
CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
|
|
JP6636673B2
(ja)
*
|
2016-10-04 |
2020-01-29 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
STINGアゴニストとしてのベンゾ[b]チオフェン化合物
|